
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen Inc. is poised for growth as it approaches the clinical initiation for its lead product candidate SZN-8141, with an increased modeled factor of wet AMD patients seeking novel treatments, now estimated at 25%. Additionally, a collaboration with Boehringer Ingelheim has resulted in a significant $5 million milestone payment for its partnered program SZN-413, underscoring the validation of Surrozen's Wnt asset development. The company’s success in preclinical studies, particularly pertaining to SZN-413, complements the promising prospects for its wholly-owned candidates, SZN-8141 and SZN-8143, indicating strong potential within the evolving therapeutic landscape for retinal diseases.
Bears say
Surrozen Inc's stock faces significant risks due to its reliance on successful capital raises, which may not occur on favorable terms, potentially leading to adverse effects on stock performance. Key concerns include the possibility that its developmental candidates may not meet peak commercial revenue expectations due to limitations in market size, penetration rates, or pricing, alongside the need for adequate capital resources to sustain operations. Additionally, the company’s lead candidate, SZN-8141, may face unexpected toxicity in early studies or potential failures in related studies by partners such as Merck, which could negatively impact the perception of the entire Wnt agonist class for retinal diseases.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares